Patents by Inventor Robert J. HASELBECK

Robert J. HASELBECK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230158088
    Abstract: Provided are compositions, including products of manufacture and kits, and methods, comprising combinations of microbes, such as non-pathogenic, live bacteria and/or bacterial spores, for the control, amelioration, prevention, and treatment of a disease or condition, for example, a viral infection such as a COVID19 infection, and these non-pathogenic, live bacteria and/or bacterial spores can be administered to an individual, thereby resulting in a modification or modulation of the individual's gut microfloral population(s), and by modulating or modifying the individual's gut microbial population(s) using compositions, products of manufacture and methods as provided herein, the pharmacodynamics or effectiveness of a drug or a vaccine administered to the individual is altered, for example, the pharmacodynamics of the drug or vaccine is enhanced, the individual's ability to absorb a drug is modified or the dose efficacy of a drug or vaccine is increased.
    Type: Application
    Filed: March 26, 2021
    Publication date: May 25, 2023
    Inventors: Stephanie J. CULLER, Robert J. HASELBECK, Stephen VAN DIEN
  • Publication number: 20220378855
    Abstract: Provided are compositions, including products of manufacture and kits, and methods, comprising combinations of microbes, such as non-pathogenic, live bacteria and/or bacterial spores, for the control, amelioration, prevention, and treatment of a disease or condition, for example, a cancer. In alternative embodiment, these non-pathogenic, live bacteria and/or bacterial spores are administered to an individual in need thereof, thereby resulting in a modification or modulation of the individual's gut microfloral population(s). In alternative embodiments, by modulating or modifying the individual's gut microbial population(s) using compositions, products of manufacture and methods as provided herein, the pharmacodynamics of a drug administered to the individual is altered, thereby controlling, ameliorating, preventing and/or treating of that cancer.
    Type: Application
    Filed: December 17, 2020
    Publication date: December 1, 2022
    Inventors: Stephanie J. CULLER, Robert J. HASELBECK, Stephen VAN DIEN, Anandh SWAMINATHAN, Hirokazu SATO
  • Patent number: 10941454
    Abstract: In alternative embodiments, provided are non-natural or genetically engineered vinylisomerase-dehydratase enzymes, including alkenol dehydratases, linalool dehydratases and crotyl alcohol dehydratases. In alternative embodiments, provided are non-natural or genetically engineered polypeptides having an activity comprising, for example, a vinylisomerase-dehydratase, an alkenol dehydratase, a linalool dehydratase and/or a crotyl alcohol dehydratase activity, or a combination thereof. In alternative embodiments, also provided are non-natural or genetically engineered nucleic acids (polynucleotides) encoding polypeptides described herein, expression or cloning vehicles comprising or having contained therein nucleic acids as described herein, and non-natural or genetically engineered cells comprising or having contained therein nucleic acids as described herein. In alternative embodiments, also provided are methods for making various organic compounds, including methyl vinyl carbinol and butadiene.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: March 9, 2021
    Assignees: GENOMATICA, INC., BRASKEM S.A.
    Inventors: Stephanie J. Culler, Robert J. Haselbeck, Harish Nagarajan, Iuri Estrada Gouvea, Daniel Johannes Koch, Mateus Schreiner Garcez Lopes, Lucas Pedersen Parizzi
  • Publication number: 20210038654
    Abstract: In alternative embodiments, provided are compositions, including products of manufacture and kits, and methods, for or comprising administering to an individual in need thereof an inhibitor of an inhibitory immune checkpoint molecule and/or a stimulatory immune checkpoint molecule and a formulation, wherein the formulation comprises at least two different species or genera of non-pathogenic, live bacteria, and each of the non-pathogenic, live bacteria comprise non-pathogenic colony forming live bacteria, a plurality of non-pathogenic germinable bacterial spores, or a combination thereof, and optionally the non-pathogenic bacteria or non-pathogenic bacteria arising from germination of the germinable spores can individually or together metabolize urolithin A from ellagic acid, or can individually or together synthesize urolithin A.
    Type: Application
    Filed: March 15, 2019
    Publication date: February 11, 2021
    Inventors: Stephanie J. CULLER, Robert J. HASELBECK, Steven VAN DIEN, Anandh SWAMINATHAN
  • Publication number: 20190010479
    Abstract: In alternative embodiments, provided are non-natural or genetically engineered vinylisomerase-dehydratase enzymes, including alkenol dehydratases, linalool dehydratases and crotyl alcohol dehydratases. In alternative embodiments, provided are non-natural or genetically engineered polypeptides having an activity comprising, for example, a vinylisomerase-dehydratase, an alkenol dehydratase, a linalool dehydratase and/or a crotyl alcohol dehydratase activity, or a combination thereof. In alternative embodiments, also provided are non-natural or genetically engineered nucleic acids (polynucleotides) encoding polypeptides described herein, expression or cloning vehicles comprising or having contained therein nucleic acids as described herein, and non-natural or genetically engineered cells comprising or having contained therein nucleic acids as described herein. In alternative embodiments, also provided are methods for making various organic compounds, including methyl vinyl carbinol and butadiene.
    Type: Application
    Filed: May 26, 2016
    Publication date: January 10, 2019
    Inventors: Stephanie J. CULLER, Robert J. HASELBECK, Harish NAGARAJAN, Iuri Estrada GOUVEA, Daniel Johannes KOCH, Mateus Schreiner Garcez LOPES, Lucas Pedersen PARIZZI